Compare ARDX & PGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARDX | PGY |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2014 | N/A |
| Metric | ARDX | PGY |
|---|---|---|
| Price | $7.99 | $21.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $12.95 | ★ $39.43 |
| AVG Volume (30 Days) | ★ 6.3M | 3.0M |
| Earning Date | 02-19-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $398,234,000.00 | ★ $1,245,946,000.00 |
| Revenue This Year | $22.65 | $28.75 |
| Revenue Next Year | $31.33 | $17.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 58.12 | 28.33 |
| 52 Week Low | $3.21 | $8.50 |
| 52 Week High | $8.17 | $44.99 |
| Indicator | ARDX | PGY |
|---|---|---|
| Relative Strength Index (RSI) | 66.23 | 43.84 |
| Support Level | $6.73 | $20.62 |
| Resistance Level | $7.25 | $26.80 |
| Average True Range (ATR) | 0.57 | 1.41 |
| MACD | 0.14 | -0.20 |
| Stochastic Oscillator | 89.03 | 20.23 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.